Quale sarebbe il prezzo per Ulisse Biomed S.p.A. (UBM)

Il prezzo per Ulisse Biomed S.p.A. (UBM) è $0.93739396

Qual è la capitalizzazione di mercato per Ulisse Biomed S.p.A. (UBM)

La capitalizzazione di mercato per Ulisse Biomed S.p.A. (UBM) è $20.44M

Ricavi di Ulisse Biomed S.p.A. (UBM)

Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.

Anno	Ricavi	Cambia
Non abbastanza dati per le date fornite.

Anno

Ricavi

Cambia

Non abbastanza dati per le date fornite.

Azienda	Ricavi	Differenza nei ricavi	Il paese
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Azienda

Ricavi

Differenza nei ricavi

Il paese